
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros Corporation has demonstrated a positive financial trajectory, with other income increasing to $2.1 million due to higher interest income from an enhanced cash balance, indicating robust liquidity. The authorization of a $100 million open-ended share repurchase program reflects management's confidence in the company's financial stability and strategic direction. Moreover, the clinical success of narsoplimab, which has shown a statistically significant survival advantage in treated patients, positions Omeros favorably within the competitive landscape of complement-targeting therapies, bolstering its prospects for future growth.
Bears say
Omeros Corp has demonstrated a decline in research and development expenses, reported at $10.1 million for Q3, which reflects the wind-down of prior clinical studies. This reduction in R&D investment raises concerns about the company’s commitment to advancing its drug pipeline, particularly for its lead candidate, narsoplimab. The strategic cessation of earlier trials may indicate potential challenges in achieving necessary clinical milestones, thereby contributing to a negative outlook for the stock.
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares